Get the Advaxis Update: http://equitiesiq.com/advaxis-update-2
NEW YORK, NY / June 18, 2014 / EquitiesIQ, a leading informational research provider, has provided an update to its coverage of Advaxis, Inc. (Nasdaq: ADXS). Advaxis is an emerging biopharmaceutical company developing proprietary Lm-LLO immunotherapies for the treatment of cancer.
Advaxis's Lm-LLO immunotherapies are based on a platform technology that uses live, attenuated bacteria to stimulate the immune system to selectively target cancer cells while reducing tumor defenses. Advaxis's lead immunotherapy, ADXS-HPV, is under investigation for the treatment of HPV-associated cancers. ADXS-HPV has demonstrated improved survival and objective tumor responses in a Phase 2 trial in 110 patients with recurrent cervical cancer.
On June 10th, Advaxis announced that its request for an End-of-Phase 2 meeting with the FDA had been granted. Advaxis will review clinical findings with the FDA in order to assess any additional information needed prior to moving ADXS-HPV forward in a pivotal Phase 3 program.
Advaxis's second immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis is planning to file an IND with the FDA and initiate a Phase 1 clinical study with ADXS-PSA in 2014. Advaxis is also developing ADXS-cHER2, to target the HER2 receptor, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, and gastric cancer. Advaxis is pursuing a clinical program in pediatric osteosarcoma.
EquitiesIQ publishes and distributes research reports that enhance the visibility of our client companies. Our reports are written by analysts who recognize investors' desire to understand a business in a way that supports an educated investment decision. To learn more about EquitiesIQ, visit the company's website, EquitiesIQ.com. EquitiesIQ is not a registered investment adviser or broker-dealer.
Important Disclosures and Disclaimers
The report described in this press release has been prepared by EquitiesIQ, LLC on behalf of Advaxis, Inc. (the "Company"), as part of investor relations services provided to Advaxis by EquitiesIQ. EquitiesIQ has been compensated for preparation of a research report and for related promotional activities, as fully disclosed by EquitiesIQ. David Moskowitz is the author of the report and the views regarding Advaxis expressed in the report accurately reflect the personal views of Mr. Moskowitz regarding Advaxis and its securities, as of the date of the report.
The research report is not an offer or solicitation to buy or sell the securities of the Advaxis. The report is for information purposes only, and is not intended to (and is provided explicitly on the condition that it not) be used as the sole basis to make any investment decision. Investors should make their own determinations whether an investment in any particular security is consistent with their investment objectives, risk tolerance, and financial situation. EquitiesIQ and its affiliates are not recommending any investments based on the information in the research report.
This press release and the research report contain forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. EquitiesIQ does not guarantee the accuracy and comprehensiveness of these predictions. You should not invest in the Advaxis in reliance on these forward-looking statements.
Please read the full disclosures and disclaimers at the end of our reports as well as the general disclaimers and terms at EquitiesIQ.com/Disclaimer.